FDA Approves Landmark Breakthrough Drug for Pancreatic Cancer, Ushering in New Era of Treatment
28.08.2026, 02:00
In a significant advancement for cancer treatment, the FDA has approved a groundbreaking drug, daraxonrasib, specifically for patients with metastatic pancreatic cancer. This approval is celebrated as a milestone, potentially doubling survival rates for afflicted individuals. The drug, branded as...